Efficacy of PERFOROMIST®
Rapid, Sustained and Consistent Delivery
Most patients with Chronic Obstructive Pulmonary Disease (COPD) have difficulty breathing and seek rapid relief. Nebulized PERFOROMIST Inhalation Solution provides long-lasting bronchodilation. It works in as soon as five minutes and lasts for 12 hours.2 It is not to be used for relief of acute episodes of bronchospasm.
Sustained FEV1 improvement over 12 hours at week 122
A randomized, double-blind, double-dummy, placeboand active-controlled, parallel-group study in 351 moderate to severe COPD patients evaluating the safety and efficacy of PERFOROMIST Solution (20 mcg/2 mL BID) over 12 weeks. Sustained improvement was measured by serial FEV1 for 12 hours postdose, the primary efficacy analysis compared with placebo when evaluated at end point. Seventy-eight percent of subjects achieved a 15% increase from baseline in FEV1 following the first dose of PERFOROMIST Solution, 20 mcg.
In a 12-week pivotal trial, twice-daily dosing with PERFOROMIST provided sustained and consistent bronchodilation at every time point measured throughout the study period.2 There was no evidence of tachyphylaxis throughout the 12 weeks.2 Tolerance to the effects of inhaled beta2-agonists can occur with regularly scheduled, chronic use.
Fewer interruptions for your patients could make a significant difference in their daily routines. Twice-daily dosing with PERFOROMIST, a long-acting beta2-agonist (LABA), provides your patients with:1,2
- Rapid relief with the morning dose to help start the day
- Symptom control throughout the night with the evening dose
Reduced Need for Rescue Medication
Reducing the need for rescue medication may indicate increased symptom control.*2
Average daily albuterol usage (puffs) over 12-week study2
* PERFOROMIST Solution has not been demonstrated to have an impact on disease progression in patients with COPD.
† LS mean = least squares mean, a method for determining the values of unknown quantities by minimizing the differences between predicted and observed values.
A randomized, double-blind, double-dummy, placebo and active-controlled, parallel-group study in 351 moderate to severe COPD patients evaluating the safety and efficacy of PERFOROMIST Solution (20 mcg/2 mL BID) over 12 weeks.
Many patients with COPD are not getting the full effect of their maintenance treatment. Consider your patients. Consider their treatment settings. Consider reevaluating the treatment strategy for your patients with COPD.
Your patients with COPD can achieve rapid and sustained bronchodilation with twice-daily nebulization—with PERFOROMIST.2